Trump Trade War: Supreme Court Decision Could Reshape Tariffs and the Economy
This outcome would create massive administrative challenges. Costco (COST) and other major importers have already filed refund claims, anticipating a favorable verdict. Hassett warned that processing such a large volume of claims would strain government systems and finances.
In response to growing public attention, Trump has floated the idea of issuing $2,000 rebate checks funded by tariff revenue.
» Read more about: Trump Trade War: Supreme Court Decision Could Reshape Tariffs and the Economy »
Read MoreNvidia and Palantir Stock: One Is Set to Rise and the Other to Fall in 2026
Nvidia (NASDAQ: NVDA) and Palantir (NASDAQ: PLTR) have been two of the faces of the artificial intelligence (AI) investment trend since it began in 2023. Each has delivered incredible shareholder returns, rising more than 2,600% (Palantir) and nearly 1,100% (Nvidia) since 2023. Each company has also had a phenomenal 2025,
» Read more about: Nvidia and Palantir Stock: One Is Set to Rise and the Other to Fall in 2026 »
Read MoreStock market today: Nasdaq, S&P 500, Dow futures rise as tech recovers, while gold climbs to record high
XRP ETFs Show Strength, Bitcoin ETF, Ethereum ETFs Bleed $490-$650M Last Week
Spot XRP ETFs in the United States have continued to show strength, clocking $82 million in inflows over the past week. The significance of these net flows is even more pronounced as Bitcoin ETFs and Ethereum ETFs bled.
Spot XRP ETFs in the US have crossed $1.2 billion in total assets under management (AUM).
» Read more about: XRP ETFs Show Strength, Bitcoin ETF, Ethereum ETFs Bleed $490-$650M Last Week »
Read MorePrediction: This Will Be 2026's Top-Performing Artificial Intelligence Stock
Key Points
The artificial intelligence (AI) buildout has been ongoing since 2023, but it’s far from over.
The Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Could Meta Be the Next $2 Trillion Titan?
With over 3.4 billion people engaging with at least one of Meta’s apps daily, the company already owns the world’s largest digital attention network. But now, it’s not just about scale, it’s about intelligence. Meta has embedded AI deep into its core product experiences, reshaping how users interact with content and how advertisers connect with audiences.
» Read more about: Could Meta Be the Next $2 Trillion Titan? »
Read MoreThe Spotlight
Spotlight: What to Buy If Things Get Crazy Soon
Among the first lessons any great investor learns is “Don’t Fight The Fed.” Simply put, it means when the Fed is accommodative and engaging in quantitative easing, money is cheap and economies boom. Some call this the Fed Put because as markets fall, the Federal Reserve acts swiftly to provide liquid support by buying bonds.
» Read more about: Spotlight: What to Buy If Things Get Crazy Soon »